Ascendis Pharma
Committed to making a meaningful difference for patients
Committed to making a meaningful difference for patients
Ascendis Pharma is a biopharmaceutical company committed to making a meaningful difference for patients. The company is guided by its core values of patients, science, and passion and is applying innovative TransCon technology to create new and potentially best-in-class therapies. Currently, Ascendis Pharma has three independent endocrinology rare disease product candidates in clinical development and is also advancing programs in Oncology and Ophthalmology. The company is headquartered in Copenhagen, Denmark with additional offices in Heidelberg, Munich, and Berlin, Germany, Palo Alto and Redwood City, California, and Princeton, New Jersey. Having been founded in 2006, Ascendis Pharma has seen significant investment, with the last investment of $150.00M Post-IPO Debt being made on 05 September 2023, with Royalty Pharma as the investors. The company operates within the Biotechnology and Health Care industries, positioning itself as an innovative leader in the field of biopharmaceuticals.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $150.00M | 1 | Royalty Pharma | 05 Sep 2023 |
| Post-IPO Debt | $500.00M | - | 24 Mar 2022 | |
| Post-IPO Equity | $690.00M | - | 07 Jul 2020 | |
| Post-IPO Equity | Unknown | 1 |
|
01 Jan 2017 |
| Series D | $60.00M | 6 |
|
01 Dec 2014 |
No recent news or press coverage available for Ascendis Pharma.
We care about your data, and we'd love to use cookies make your experience better.
